Sydnexis Announces Three Abstracts Accepted for Poster Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting

DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc., (www.sydnexis.com) a pre-commercial stage biopharmaceutical company, announces that three abstracts have been accepted for poster presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting taking place from May 4 to 8 in Salt Lake City, UT. These posters present clinical data related to the STAR Study, Sydnexis’ groundbreaking pivotal phase 3 clinical trial evaluating SYD-101, a novel and proprietary l